{
    "Trade/Device Name(s)": [
        "CR3 Keyless Split Sample Cup Oxycodone - Cannabinoids"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K150179",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122904"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "LDJ"
    ],
    "Summary Letter Date": "January 23, 2015",
    "Summary Letter Received Date": "January 27, 2015",
    "Submission Date": "February 18, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3650",
        "21 CFR 862.3870"
    ],
    "Regulation Name(s)": [
        "Opiate test system",
        "Cannabinoid test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxycodone",
        "Cannabinoids",
        "11-nor-\u03949-THC-9-COOH"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow assay"
    ],
    "Methodologies": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay"
    ],
    "Submission Type(s)": [
        "Test",
        "Cup",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for CR3 Keyless Split Sample Cup Oxycodone - Cannabinoids rapid urine test for qualitative detection of oxycodone and cannabinoids",
    "Indications for Use Summary": "Qualitative detection of oxycodone and cannabinoids in human urine at 100 ng/mL and 50 ng/mL cutoffs, respectively, as the first step in a two-step process for over-the-counter and prescription use.",
    "fda_folder": "Toxicology"
}